The concept of Open Source Pharma (OSP) is a concept inspired by Open Source Software principles and dates to 2006. Adapted to tackling important public health challenges, The Open Source Pharma Foundation got its beginnings in 2015 funded by Tata Trust, The Rockefeller Foundation, Wellcome Trust, and the India Health Fund. The organization hopes to catalyze a radical change in the way we do medical Research & Development (R&D) and deliver better and more affordable innovation quicker and cheaper. It relies on crowdsourced, computer-driven drug discovery, Information Technology (IT)-enabled clinical trials with open data, and alternative approaches to Intellectual Property and generics manufacturing. It is playing an important role in the worldwide pandemic by partnering with the Harvard School of Medicine and the Government of India, a collaborative group that is close to launching multiple Phase 3 COVID-19 vaccine trials. Through this venture — OpenVax — the Open Source Pharma Foundation is fighting not only COVID-19 but future pandemics by rapidly and equitably repurposing existing widely-available, off-patent, low-cost vaccines with strong safety records. Simultaneously, they have partnered with the European Vaccine Initiative (EVI) to develop a computational platform to develop a COVID-19 vaccine. The Foundation operates centers in India, France and New York City.